{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:20:12Z","timestamp":1792664412876,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jdin.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T22:06:27Z","timestamp":1665439587000},"page":"14-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6807-6042","authenticated-orcid":false,"given":"Angela L.","family":"Bosma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Ouwerkerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline J.","family":"Heidema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Prieto-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Ardern-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Ogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M. Ross","family":"Hearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari\u00ebnna M.","family":"Hyseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise A.A.","family":"Gerbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis I.","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza A.","family":"Middelkamp-Hup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.jdin.2022.09.006_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0190-9622(95)90128-0","article-title":"London-born black Caribbean children are at increased risk of atopic dermatitis","volume":"32","author":"Williams","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2022.09.006_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.jdin.2022.09.006_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2022.09.006_bib5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","article-title":"Endophenotypic variations of atopic dermatitis by age, race, and ethnicity","volume":"8","author":"Nomura","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/pai.13335","article-title":"Global differences in atopic dermatitis","volume":"32","author":"Suaini","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib7","first-page":"30","article-title":"Pruritus in black skin: unique molecular characteristics and clinical features","volume":"113","author":"McColl","year":"2021","journal-title":"J Natl Med Assoc"},{"issue":"12","key":"10.1016\/j.jdin.2022.09.006_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00128071-200304120-00004","article-title":"Racial (ethnic) differences in skin properties: the objective data","volume":"4","author":"Wesley","year":"2003","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjd.16994","article-title":"A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis","volume":"180","author":"Hulshof","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib10","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1038\/s41598-019-43128-3","article-title":"Reconstructed skin models revealed unexpected differences in epidermal African and Caucasian skin","volume":"9","author":"Girardeau-Hubert","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jdin.2022.09.006_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ics.12321","volume":"38","author":"Raj","year":"2016","journal-title":"Int J Cosmet Sci"},{"issue":"4","key":"10.1016\/j.jdin.2022.09.006_bib12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clindermatol.2017.03.007","article-title":"Typical and atypical clinical appearance of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.09.006_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","article-title":"A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics","volume":"80","author":"Yew","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2022.09.006_bib14","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled Phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/DER.0000000000000517","article-title":"Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis","volume":"31","author":"Napolitano","year":"2020","journal-title":"Dermatitis"},{"issue":"9","key":"10.1016\/j.jdin.2022.09.006_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092684","article-title":"Efficacy of dupilumab on different phenotypes of atopic dermatitis: one-year experience of 221 patients","volume":"9","author":"Tavecchio","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13290","article-title":"Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults","volume":"33","author":"Patruno","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jdin.2022.09.006_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1468-3083.2011.04142.x","article-title":"Tapering cyclosporine after long-term treatment of atopic dermatitis","volume":"26","author":"Frankel","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jdin.2022.09.006_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1525-1470.2011.01488.x","article-title":"Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil","volume":"28","author":"Waxweiler","year":"2011","journal-title":"Pediatr Dermatol"},{"issue":"11","key":"10.1016\/j.jdin.2022.09.006_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamadermatol.2014.1674","article-title":"Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States","volume":"150","author":"Bhattacharya","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.09.006_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjd.16714","article-title":"TREatment of ATopic eczema (TREAT) registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries","volume":"180","author":"Gerbens","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjd.17715","article-title":"TREatment of ATopic eczema (TREAT) registry Taskforce: consensus on how\u00a0and when to measure the core dataset for atopic eczema\u00a0treatment research registries","volume":"181","author":"Vermeulen","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.09.006_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2022.09.006_bib25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the\u00a0patients' perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.09.006_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaip.2017.07.007","article-title":"Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a Phase III randomized noninferiority trial","volume":"6","author":"Goujon","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.12820","article-title":"Methotrexate vs. ciclosporin in the treatment of severe atopic dermatitis in children: a critical appraisal","volume":"170","author":"Tsakok","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.jdin.2022.09.006_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.jdin.2022.09.006_bib31","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2340\/00015555-2433","article-title":"Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch","volume":"96","author":"Reich","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jdin.2022.09.006_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1346-8138.15750","article-title":"Children with atopic eczema experiencing increased disease severity in the pollen season more often have hay fever at a young age and a dark skin type","volume":"48","author":"Bosma","year":"2021","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2022.09.006_bib33","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2020.05.128","article-title":"Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, The Netherlands) registry","volume":"83","author":"Bosma","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2022.09.006_bib34","first-page":"650","article-title":"Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study","volume":"112","author":"Bell","year":"2020","journal-title":"J Natl Med Assoc"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/09546634.2017.1365112","article-title":"Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace","volume":"29","author":"Alexander","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"10.1016\/j.jdin.2022.09.006_bib36","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1038\/jid.2015.296","article-title":"Psoriasis in the US medicare population: prevalence, treatment, and factors associated with biologic use","volume":"135","author":"Takeshita","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2022.09.006_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037518","article-title":"Epidemiology and management of atopic dermatitis in England: an observational cohort study protocol","volume":"10","author":"de Lusignan","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/cea.13783","article-title":"Patterns and trends in eczema management in UK primary care (2009-2018): a population-based cohort study","volume":"51","author":"de Lusignan","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.jdin.2022.09.006_bib39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/cea.13784","article-title":"The epidemiology of eczema in children and adults in England: a population-based study using primary care data","volume":"51","author":"de Lusignan","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"10.1016\/j.jdin.2022.09.006_bib40","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archderm.1995.01690220040008","article-title":"Skin type, but neither race nor gender, influence epidermal permeability barrier function","volume":"131","author":"Reed","year":"1995","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2022.09.006_bib41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0190-9622(81)70105-1","article-title":"Percutaneous penetration of dipyrithione in man: effect of skin color (race)","volume":"5","author":"Wedig","year":"1981","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.09.006_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5415\/apallergy.2011.1.2.80","article-title":"Clinical features of the extrinsic and intrinsic types of adult-onset atopic dermatitis","volume":"1","author":"Kulthanan","year":"2011","journal-title":"Asia Pac Allergy"},{"issue":"5","key":"10.1016\/j.jdin.2022.09.006_bib43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1525-1470.2012.01739.x","article-title":"Less common clinical manifestations of atopic dermatitis: prevalence by age","volume":"29","author":"Juli\u00e1n-G\u00f3nzalez","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2022.09.006_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1525-1470.1998.tb01362.x","article-title":"Epidemiology and clinical pattern of atopic dermatitis in a North Indian pediatric population","volume":"15","author":"Dhar","year":"1998","journal-title":"Pediatr Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266632872200133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266632872200133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:00:08Z","timestamp":1762981208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266632872200133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"alternative-id":["S266632872200133X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2022.09.006","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}